Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 17/20 | 0.77 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4162229 | 1.00 | BDKRB1 (0.77) | BDKRB1CCR2KCNH2MEN1KMT2A | |
| SCHEMBL4180713 | 0.97 | BDKRB1 (0.78) | BDKRB1 | |
| SCHEMBL4180710 | 0.97 | BDKRB1 (0.78) | BDKRB1 | |
| SCHEMBL4172251 | 0.92 | BDKRB1 (0.77) | BDKRB1 | |
| SCHEMBL4172325 | 0.92 | BDKRB1 (0.77) | BDKRB1 | |
| SCHEMBL4754139 | 0.91 | BDKRB1 (0.78) | BDKRB1MEN1KMT2AHCRTR1HCRTR2 | |
| SCHEMBL4754141 | 0.91 | BDKRB1 (0.78) | BDKRB1MEN1KMT2AHCRTR1HCRTR2 | |
| SCHEMBL4184132 | 0.90 | BDKRB1 (0.77) | BDKRB1MEN1KMT2AHCRTR1HCRTR2 | |
| SCHEMBL4184135 | 0.90 | BDKRB1 (0.77) | BDKRB1MEN1KMT2AHCRTR1HCRTR2 | |
| SCHEMBL4177061 | 0.87 | BDKRB1 (1.00) | BDKRB1MEN1KMT2AHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | AMGEN INC. (US) | 2009-09-10 | — | — | US | claimed |
| EP-1963285-A1 | BRADYKININ 1 RECEPTOR ANTAGONISTS | Amgen Inc. (US) | 2008-09-03 | — | — | EP | claimed |
| WO-2007067629-A1 | BRADYKININ 1 RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 2007-06-14 | — | — | WO | claimed |
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | AMGEN INC. (US) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | BDKRB1, BDKRB2, VIPR1 | BDKRB1 1/4885CCR2 423/4885KCNH2 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.